Headlands Technologies LLC Takes Position in AtriCure, Inc. $ATRC

Headlands Technologies LLC purchased a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 10,064 shares of the medical device company’s stock, valued at approximately $282,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ATRC. AQR Capital Management LLC increased its holdings in AtriCure by 1.0% in the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after buying an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in AtriCure by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after purchasing an additional 1,230 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock valued at $27,830,000 after acquiring an additional 8,956 shares in the last quarter. Jane Street Group LLC increased its position in shares of AtriCure by 658.3% during the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after purchasing an additional 87,553 shares during the period. Finally, Strs Ohio bought a new stake in AtriCure in the first quarter worth about $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at AtriCure

In other AtriCure news, insider Justin Noznesky sold 6,182 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the transaction, the insider owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This represents a 5.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Karen Prange sold 3,564 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares of the company’s stock, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,379 shares of company stock worth $2,557,552 over the last three months. 4.00% of the stock is owned by corporate insiders.

AtriCure Trading Down 1.8%

NASDAQ ATRC opened at $51.52 on Friday. The company has a market cap of $2.62 billion, a PE ratio of 245.35 and a beta of 1.26. The stock has a 50 day moving average of $40.10 and a 200-day moving average of $32.83. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $53.50. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter last year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts anticipate that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

ATRC has been the subject of a number of recent analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. UBS Group lowered their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. BTIG Research raised their price objective on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Piper Sandler increased their price objective on shares of AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Finally, Needham & Company LLC increased their target price on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $52.00.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.